| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Cinnamtannin B2 does not have a single defined molecular target; as a polyphenolic tannin, it exhibits broad biological activities through non-specific interactions with proteins and enzymes, including antioxidant effects via free radical scavenging and metal chelation, and inhibition of various enzymes such as glucosidases and lipases through polyphenol-protein interactions.
|
|---|---|
| ln Vitro |
Cinnamtannin B2 demonstrates potent antioxidant activity in various cell-free assays including DPPH, ABTS, and FRAP radical scavenging tests. It exhibits α-glucosidase and pancreatic lipase inhibitory activities, contributing to potential anti-diabetic and anti-obesity effects. It also shows anti-inflammatory activity through inhibition of pro-inflammatory mediators and cytokine production in activated immune cells.
|
| ln Vivo |
Cinnamtannin B2 exhibits in vivo antioxidant and anti-inflammatory activities in rodent models. It can attenuate oxidative stress markers and inflammatory responses. It shows potential hypoglycemic effects by inhibiting carbohydrate-digesting enzymes and improving insulin sensitivity in diabetic animal models. It also demonstrates hepatoprotective effects against chemically induced liver damage through its antioxidant properties.
|
| Enzyme Assay |
Cell-free enzyme inhibition assays for Cinnamtannin B2: α-glucosidase or pancreatic lipase is incubated with varying concentrations of the compound (0-1000 µM) in appropriate assay buffers at 37°C. Following incubation, substrate (e.g., p-nitrophenyl-α-D-glucopyranoside for α-glucosidase) is added, and the release of chromogenic product is measured spectrophotometrically at 405 nm. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Cinnamtannin B2: cells (e.g., HepG2 hepatocytes or RAW 264.7 macrophages) are cultured in DMEM with 10% FBS and treated with various compound concentrations (0.1-100 µM) for 24-48 hours. Cell viability is assessed via MTT assay. Anti-inflammatory activity is evaluated by measuring cytokine levels (TNF-α, IL-6) using ELISA after LPS stimulation.
|
| Animal Protocol |
In vivo animal studies for Cinnamtannin B2: rodent models (e.g., C57BL/6 mice or Sprague-Dawley rats) are administered the compound orally or intraperitoneally at doses of 10-100 mg/kg. For diabetic models, streptozotocin or high-fat diet is used to induce diabetes, and blood glucose, insulin levels, and lipid profiles are measured. Tissue oxidative stress markers (MDA, SOD, GSH) are assessed post-treatment.
|
| ADME/Pharmacokinetics |
Limited pharmacokinetic data are available for Cinnamtannin B2. As a high-molecular-weight polyphenol, it likely has poor oral bioavailability due to low intestinal absorption and extensive metabolism by gut microbiota. Peak plasma concentrations are expected within 1-4 hours after oral administration. The compound is extensively metabolized to smaller phenolic acids and conjugates, with elimination primarily via feces and urine.
|
| Toxicity/Toxicokinetics |
Acute toxicity studies for Cinnamtannin B2 are limited. Related proanthocyanidins are generally considered safe at moderate doses, with no significant toxicity observed in animal studies at doses up to 500 mg/kg. However, high doses may cause gastrointestinal discomfort due to tannin-protein interactions. Long-term safety data are lacking, and the compound has not been approved for clinical use.
|
| References | |
| Additional Infomation |
Cinnamtannin B2 is a benzopyran compound. It has been reported to exist in plants of the genus Cinnamomum (such as Cinnamomum iners and Cinnamomum sieboldii) and other organisms with relevant data. See also: Cinnamon (partial); Chinese Cinnamon (partial).
Cinnamtannin B2 is a research compound not approved for clinical use. Its primary applications are in nutraceutical and functional food research due to its antioxidant properties. As a natural product, its mechanism involves modulation of oxidative stress pathways and enzyme inhibition. The compound is available as a reference standard for analytical and pharmacological studies. |
| Molecular Formula |
C60H48O24
|
|---|---|
| Molecular Weight |
1153.01
|
| Exact Mass |
1152.25
|
| CAS # |
88038-12-4
|
| PubChem CID |
16130973
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.691
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
84
|
| Complexity |
2280
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O[C@@H]1[C@H]2C3C4O[C@H](C5C=CC(O)=C(O)C=5)[C@@H]([C@H](C=4C(O)=CC=3O[C@]1(C1C=CC(O)=C(O)C=1)OC1C([C@@H]3[C@@H](O)[C@@H](C4C=CC(O)=C(O)C=4)OC4C=C(C=C(C3=4)O)O)=C(O)C=C(O)C=12)C1C(O)=CC(O)=C2C[C@H]([C@@H](C3C=CC(O)=C(O)C=3)OC=12)O)O
|
| InChi Key |
QRQAODSINXAOBF-UKTWWWBFSA-N
|
| InChi Code |
InChI=1S/C60H48O24/c61-23-13-34(71)42-40(14-23)80-54(20-2-6-26(63)31(68)10-20)51(77)48(42)45-36(73)17-37(74)46-50-47-41(83-60(59(50)79,84-58(45)46)22-4-8-28(65)33(70)12-22)18-38(75)44-49(52(78)55(82-57(44)47)21-3-7-27(64)32(69)11-21)43-35(72)16-29(66)24-15-39(76)53(81-56(24)43)19-1-5-25(62)30(67)9-19/h1-14,16-18,39,48-55,59,61-79H,15H2/t39-,48-,49+,50-,51-,52-,53-,54-,55-,59-,60-/m1/s1
|
| Chemical Name |
(1R,5R,6R,7S,13R,21R)-5,13-bis(3,4-dihydroxyphenyl)-7-[(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-8-yl]-16-[(2R,3R,4R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-4-yl]-4,12,14-trioxapentacyclo[11.7.1.02,11.03,8.015,20]henicosa-2(11),3(8),9,15,17,19-hexaene-6,9,17,19,21-pentol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8673 mL | 4.3365 mL | 8.6730 mL | |
| 5 mM | 0.1735 mL | 0.8673 mL | 1.7346 mL | |
| 10 mM | 0.0867 mL | 0.4336 mL | 0.8673 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
